文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

急性肾损伤患者静脉注射对比剂后的肾脏结局:多中心回顾性倾向调整分析

Renal outcomes following intravenous contrast administration in patients with acute kidney injury: a multi-site retrospective propensity-adjusted analysis.
PubMed 文献 · Intensive Care Med · 2023-01-30
一句话结论在已有急性肾损伤(AKI)的患者中,静脉注射对比剂与出院时持续性AKI或180天内启动透析均无关联,目前对稳定性肾病患者使用静脉对比剂的共识推荐可能也适用于已有AKI的患者。

本研究为多中心回顾性倾向加权和熵平衡观察性队列分析,纳入2017年7月1日至2021年6月30日期间就诊于三个急诊科、到达时符合KDIGO肌酐标准AKI的≥18岁连续住院患者,比较接受与未接受静脉对比剂者的结局。共纳入14449次患者就诊,12.8%入住ICU,18.4%接受了对比剂,69.1%出院前AKI缓解。经未调整多因素logistic回归(OR 1;95%CI 0.89-1.11)、倾向加权(OR 0.93;95%CI 0.83-1.05)和熵平衡(OR 0.94;95%CI 0.83-1.05)分析,静脉对比剂与持续性AKI均无关联;ICU亚组结果相似。队列中5.4%在180天内启动透析,未观察到对比剂与180天内透析风险增加相关。作者结论认为,对已有AKI的患者,使用对比剂与出院时持续性AKI或180天内启动透析均无关联,目前对稳定性肾病患者使用静脉对比剂的共识推荐可能也适用于已有AKI的患者。

要点

  • 在已有AKI的急诊住院患者中,接受静脉对比剂者出院时持续性AKI的风险与未接受者无显著差异(倾向加权OR 0.93;95%CI 0.83-1.05;熵平衡OR 0.94;95%CI 0.83-1.05)。
  • ICU亚组分析结果与总体一致,未观察到对比剂与持续性AKI的关联。
  • 队列中180天内启动透析的发生率为5.4%,未观察到对比剂与180天内透析风险增加相关。
  • 共纳入14449次就诊,18.4%接受静脉对比剂,69.1%出院前AKI缓解;作者认为现有对稳定性肾病患者使用静脉对比剂的共识推荐可能也适用于已有AKI的患者。

适用人群与场景

  • ≥18岁、到达急诊科时符合KDIGO肌酐标准AKI的连续住院患者,就诊时间2017年7月1日至2021年6月30日,来自三个急诊科。
  • 研究比较接受与未接受静脉对比剂的患者;12.8%入住ICU。

诊断标准与关键阈值

  • AKI诊断采用KDIGO肌酐标准。

研究设计与关键结果

  • 研究类型:多中心回顾性倾向加权和熵平衡观察性队列分析;纳入14449次患者就诊,12.8%入住ICU,18.4%接受静脉对比剂,69.1%出院前AKI缓解。
  • 主要终点:出院时持续性AKI。未调整多因素logistic回归OR 1(95%CI 0.89-1.11);倾向加权OR 0.93(95%CI 0.83-1.05);熵平衡OR 0.94(95%CI 0.83-1.05),均无显著关联。
  • ICU亚组分析结果与总体相似。
  • 次要终点:180天内启动透析,发生率5.4%;未观察到对比剂与180天内透析风险增加相关。

证据类型、等级与局限

  • 证据类型:多中心回顾性观察性队列分析,采用倾向加权和熵平衡调整混杂。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对已有AKI的患者,静脉对比剂与出院时持续性AKI或180天内启动透析均无关联;目前对稳定性肾病患者使用静脉对比剂的共识推荐可能也适用于已有AKI的患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Evidence of an association between intravenous contrast media (CM) and persistent renal dysfunction is lacking for patients with pre-existing acute kidney injury (AKI). This study was designed to determine the association between intravenous CM administration and persistent AKI in patients with pre-existing AKI.

METHODS: A retrospective propensity-weighted and entropy-balanced observational cohort analysis of consecutive hospitalized patients ≥ 18 years old meeting Kidney Disease Improving Global Outcomes (KDIGO) creatinine-based criteria for AKI at time of arrival to one of three emergency departments between 7/1/2017 and 6/30/2021 who did or did not receive intravenous CM. Outcomes included persistent AKI at hospital discharge and initiation of dialysis within 180 days of index encounter.

RESULTS: Our analysis included 14,449 patient encounters, with 12.8% admitted to the intensive care unit (ICU). CM was administered in 18.4% of all encounters. AKI resolved prior to hospital discharge for 69.1%. No association between intravenous CM administration and persistent AKI was observed after unadjusted multivariable logistic regression modeling (OR 1; 95% CI 0.89-1.11), propensity weighting (OR 0.93; 95% CI 0.83-1.05), and entropy balancing (OR 0.94; 95% CI 0.83-1.05). Sub-group analysis in those admitted to the ICU yielded similar results. Initiation of dialysis within 180 days was observed in 5.4% of the cohort. An association between CM administration and increased risk of dialysis within 180 days was not observed.

CONCLUSION: Among patients with pre-existing AKI, contrast administration was not associated with either persistent AKI at hospital discharge or initiation of dialysis within 180 days. Current consensus recommendations for use of intravenous CM in patients with stable renal disease may also be applied to patients with pre-existing AKI.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Ehmann MR, Mitchell J, Levin S, et al. Renal outcomes following intravenous contrast administration in patients with acute kidney injury: a multi-site retrospective propensity-adjusted analysis. Intensive Care Med. 2023. PMID: 36715705. doi:10.1007/s00134-022-06966-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。